Decibel Appoints Jeff Jonas To Board
This article was originally published in Scrip
Executive Summary
Decibel Therapeutics has appointed SAGE Therapeutics' CEO, Jeff Jonas, to its board of directors. Jonas has been CEO of SAGE since 2013 and prior to this he was at Shire Plc., where he was most recently president of the regenerative medicine division and before that senior vice-president of R&D pharmaceuticals. Before Shire, Jonas held senior-level positions at ISIS Pharmaceuticals, Forest Laboratories Inc. and Upjohn Laboratories. He also founded AVAX Technologies and SCEPTOR Industries and served on the board for Cara Therapeutics, Inc. and AVAX Technologies.